Unbound MEDLINE

A novel neuroprotectant against retinal ganglion cell damage in a glaucoma model and an optic nerve crush model in the rat. Investigative ophthalmology & visual science. [Invest Ophthalmol Vis Sci] Journal article

 
TitleA novel neuroprotectant against retinal ganglion cell damage in a glaucoma model and an optic nerve crush model in the rat.
Author(s)Maeda K, Sawada A, Matsubara M, Nakai Y, Hara A, Yamamoto T 
InstitutionDepartment of Ophthalmology, Gifu University School of Medicine, Gifu, Japan.
SourceInvest Ophthalmol Vis Sci 2004 Mar; 45(3):851-6.
MeSHAnimals
Cell Count
Cell Death
Cell Survival
Diethylamines
Disease Models, Animal
Intraocular Pressure
Male
Nerve Crush
Neuroprotective Agents
Ocular Hypertension
Optic Nerve
Optic Nerve Diseases
Rats
Rats, Wistar
Research Support, Non-U.S. Gov't
Retinal Ganglion Cells
Thiophenes
AbstractPURPOSE: To investigate the effects of repeated treatments with a neuroprotective compound, R(-)-1-(benzo [b] thiophen-5-yl)-2-[2-(N, N-diethylamino) ethoxy] ethanol hydrochloride (T-588), on retinal ganglion cell (RGC) survival in rat eyes with elevated intraocular pressure (IOP) or after optic nerve crush.
METHODS: An increase in IOP was induced by a single laser treatment to the trabecular meshwork in one eye of adult Wistar rats. Crush injury was unilaterally produced by clipping the optic nerve 2 mm behind the globe. RGC density was estimated by counting fluorescent dye-labeled cells in the flatmount of the retina. The optic nerve damage in the crush model was also evaluated histologically.
RESULTS: In the elevated IOP model, RGC survival decreased to 72.9% +/- 3.8% (mean +/- SEM) of that of the contralateral control eye on the eighth day after laser irradiation. Repeated treatments with T-588 at 30 mg/kg twice daily significantly enhanced RGC survival (86.0% +/- 2.2%, P = 0.0242) without the reduction of IOP. In the optic nerve crush model, RGC survival diminished to 37.2% +/- 8.4% of that of the contralateral control eye after 4 weeks. Repeated applications with T-588 at 10 mg/kg twice daily significantly enhanced RGC survival (77.8% +/- 2.1%, P = 0.0038). Histologically, the rat optic nerve in the group treated with T-588 at 10 mg/kg retained a near-normal morphology.
CONCLUSIONS: T-588 has a neuroprotective effect against RGC death caused by elevated IOP and optic nerve crush in the rat.
Languageeng
Pub Type(s)Journal Article
PubMed ID14985301
  
Advertise on this site.